Related Experiment Video

Updated: Mar 28, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.4K

The development of PARP inhibitors in ovarian cancer: from bench to bedside

Yvette Drew1,2

  • 1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.

British Journal of Cancer
|December 17, 2015
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel treatment for ovarian cancer. Research over 50 years led to the 2015 approval of olaparib for BRCA-mutated ovarian cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The nuclear enzyme poly (ADP-ribose) polymerase (PARP) has emerged as a significant therapeutic target in ovarian cancer treatment.
  • Over five decades of research have elucidated the role of PARP enzymes.

Purpose of the Study:

  • To provide a historical overview of PARP research in ovarian cancer.
  • To highlight the development and approval of PARP inhibitors.

Main Methods:

  • Literature review of PARP enzyme discovery and development of inhibitors.
  • Chronological analysis of key research milestones.

Main Results:

  • The first PARP enzyme was discovered in 1963.
  • The first PARP inhibitor, olaparib (Lynparza), was approved in 2015 for BRCA-mutated ovarian cancer.

Conclusions:

  • PARP inhibitors represent a major advancement in ovarian cancer therapy.
  • Continued research into PARP pathways may yield further therapeutic strategies.

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K
Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

40.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
20